SEC Tracker
Get the app

ADC Therapeutics ADCT

ADC Therapeutics reports $25.3 million net loss

ADC Therapeutics (ADCT) filed a 10-Q with the SEC on Nov 9, 2026, 4:12 pm ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $21.72 million for the three months ended Sep 30, 2026
  2. Net loss: $25.3 million for the three months ended Sep 30, 2026
  3. Cash and equivalents: $189.2 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when ADC Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Data on this page was fetched . The filing on SEC.gov is the record.